Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G. Rossi D, et al. Among authors: gentile m. Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14. Blood. 2015. PMID: 26276669 Free PMC article. Clinical Trial.
Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F, Voso MT, Hohaus S, Gentile M, Vigna E, Recchia AG, Iovino L, Benedetti E, Lo-Coco F, Galimberti S. Morabito F, et al. Among authors: gentile m. Expert Opin Investig Drugs. 2016 Sep;25(9):1117-31. doi: 10.1080/13543784.2016.1216971. Epub 2016 Aug 8. Expert Opin Investig Drugs. 2016. PMID: 27485472 Review.
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. Condoluci A, et al. Among authors: gentile m. Blood. 2020 May 21;135(21):1859-1869. doi: 10.1182/blood.2019003453. Blood. 2020. PMID: 32267500 Free PMC article.
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Gentile M, Martino EA, Visentin A, Coscia M, Reda G, Sportoletti P, Mauro FR, Laurenti L, Varettoni M, Murru R, Chiarenza A, Vigna E, Mendicino F, Lucia E, Bossio S, Recchia AG, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vitale C, Tripepi G, D'Arrigo G, Angeletti I, Bomben R, Neri A, Cutrona G, Fronza G, Di Raimondo F, Gaidano G, Cuneo A, Foà R, Ferrarini M, Trentin L, Gattei V, Morabito F. Gentile M, et al. Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3. Blood Cancer J. 2020. PMID: 32938904 Free PMC article. No abstract available.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Vitale C, Salvetti C, Griggio V, Porrazzo M, Schiattone L, Zamprogna G, Visentin A, Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M, Pennese E, Gentile M, Boccellato E, Perutelli F, Montalbano MC, De Paoli L, Reda G, Orsucci L, Trentin L, Cuneo A, Tedeschi A, Scarfò L, Gaidano G, Mauro FR, Foà R, Boccadoro M, Coscia M. Vitale C, et al. Among authors: gentile m. Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201. Blood. 2021. PMID: 33651883 Free article. Clinical Trial.
1,320 results